TY - JOUR
T1 - Clinical Evaluation of MJD-1741 for Herpes Simplex
AU - Ando, Masaaki
AU - Sato, Hidetugu
AU - Kokubu, Jun
AU - Shimizu, Tadamichi
AU - Muramatu, Ryuichi
AU - Yamanaka, Kiyomitu
AU - Ohkawara, Akira
PY - 1990
Y1 - 1990
N2 - The clinical efficacy and safety of 3% vidarabine ointment (MJD-1741) were evaluated in 38 patients with herpes simplex virus infections. The 38 patients comprised of 3l herpes labialis's, 2 Kaposi's varicelliform eruption, one herpes genitalis, two herpes facial infections, and one each of the buttocks and the hand and lips. The effectiveness rate, which means the percentage of patients with a “moderate improvement” or better response, in patients with herpes simplex was 50.0%. And the percentage of patients with “slight improvement” or better response was 81.6%. The treatment of MJD-1741 was shown to cause neither side effects nor any abnormal laboratory findings.
AB - The clinical efficacy and safety of 3% vidarabine ointment (MJD-1741) were evaluated in 38 patients with herpes simplex virus infections. The 38 patients comprised of 3l herpes labialis's, 2 Kaposi's varicelliform eruption, one herpes genitalis, two herpes facial infections, and one each of the buttocks and the hand and lips. The effectiveness rate, which means the percentage of patients with a “moderate improvement” or better response, in patients with herpes simplex was 50.0%. And the percentage of patients with “slight improvement” or better response was 81.6%. The treatment of MJD-1741 was shown to cause neither side effects nor any abnormal laboratory findings.
UR - http://www.scopus.com/inward/record.url?scp=85007731720&partnerID=8YFLogxK
U2 - 10.2336/nishinihonhifu.52.365
DO - 10.2336/nishinihonhifu.52.365
M3 - 学術論文
AN - SCOPUS:85007731720
SN - 0386-9784
VL - 52
SP - 365
EP - 370
JO - Nishinihon Journal of Dermatology
JF - Nishinihon Journal of Dermatology
IS - 2
ER -